Abstract
In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation). © 2009.
Author supplied keywords
Cite
CITATION STYLE
APA
Recker, R. R., Lewiecki, E. M., Miller, P. D., & Reiffel, J. (2009). Safety of Bisphosphonates in the Treatment of Osteoporosis. American Journal of Medicine, 122(2 SUPPL.). https://doi.org/10.1016/j.amjmed.2008.12.004
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free